Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:
SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute/National Institutes of Health (NCI/NIH).
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
Click here to view a complete listing of these institutions.
There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. Food and Drug Administration.
To this end, SITC took the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.
Hello SITC community! I will appreciate any insights going forward for AML patients who have progressed after receiving allogeneic BMT and currently enrolled for treatment with Gilteritinib. Will such patients benefit from currently approved immunotherapies ...
This message was posted by a user wishing to remain anonymous Given that each cytokine degrades at different points in the media...while setting up a multiplex in vitro cytokine profiling assay, (with PBMCs post treatment) what is the best time point ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
Animal models have shown intestinal microbiota are crucial for therapeutic efficacy for CTLA4 blockade ( has decreased tumor size) and anti-PD1 psychotherapies.That the microbiome may be a target that can be modulated to enhance treatment responses. Theoretically, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com